GETT
17.5.2021 13:02:09 CEST | Business Wire | Press release
Gett, the leading corporate Ground Transportation Management (GTM) platform and B2B marketplace, is supporting the UK government Department for Transport and its Global Travel Taskforce with the safe return of international travel.
Gett’s ground transportation B2B marketplace now provides its clients with updates from the UK Government’s ‘traffic light’ system, supporting partners and users worldwide for the safe return of international travel. On its platform, Gett will update users with information on testing, quarantining, and travel restrictions to allow passengers access to information and government guidelines in relation to the next phase of re-opening the UK economy. This initiative supports Gett’s desire to assist employers to satisfy their duty of care obligations towards their employees, by providing users with access to information for safe travel.
As announced by the UK government on 9 April 2021, the ‘traffic light’ system applies different risk-based restrictions for passengers returning to the UK. Those travelling from ‘green’ countries require a negative Covid-19 test prior to departure but do not have to isolate when coming back into the UK, whilst travellers returning from ‘amber’ countries similarly require a negative pre-departure Covid-19, but also must isolate at home for 10 days upon their return and get a PCR test on days 2 and 8. Travellers from ‘red’ countries additionally require a negative Covid-19 test prior to departure and must isolate in specified hotels for 10 days.
Currently serving more than a quarter of Fortune 500 companies, Gett‘s unique position as a B2B marketplace for ground transportation management makes Gett a valuable partner for the UK government’s reopening of corporate travel. Gett has recently strengthened its international offering, with further expansion into the US market through the continued growth of global partner fleets. This includes the previously announced partnership with e-fleet operator Curb Mobility , joining a portfolio of existing corporate fleet, ride-hailing, taxi, and limo providers, including Lyft and Ola .
Andrew Verbitsky, Deputy CEO of Gett, commented: “The safe resumption of international travel is essential to restarting the corporate travel sector and supporting and enabling global economic recovery. Gett, as the leading corporate Ground Transportation Management (GTM) platform and B2B marketplace, is uniquely positioned to be a valued partner in this important milestone for the UK and global economy. Gett is committed to the safe resumption of corporate travel for its B2B clients and their employees.”
About Gett
Gett is a technology platform solely focused on corporate Ground Transportation Management (GTM), a market worth $79.6B globally. https://bit.ly/2SEIV3M
Gett is the GTM category leader, serving over a quarter of the Fortune 500 companies.
Gett’s cloud-based software aggregates existing transportation providers onto a single platform, helping businesses manage all of their ground transportation spend. Additionally, Gett expands companies’ coverage by connecting them to a grid of transportation providers globally.
Gett organises corporate fleet, ride-hailing, taxi, and limo providers on one platform, optimising the entire employee experience, from booking and riding to invoicing and analytics, saving businesses time and money.
Founded in 2010 and headquartered in London, Gett has raised more than $750M in funding to date, including more than $300M from the Volkswagen Group.
-ENDS-
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom